www.novonordisk.com Open in urlscan Pro
2a02:26f0:2100::215:6d3a  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Novo Nordisk Global
Press releases / News Details
 * Disease areas
 * Science & technology
 * Partnering
 * Sustainable business
 * Careers
 * About us
 * Our products
 * 

 * Investors
 * News & media
 * Patient help
 * Healthcare professionals
 * Contact us


 * Disease areas
   * Type 1 diabetes
   * Type 2 diabetes
   * Obesity
   * Growth disorders
   * Haemophilia
   * Sickle Cell Disease
   * MASH (also known as NASH)
   * Cardiovascular disease
   * Alzheimer's disease
   * Primary Hyperoxaluria
 * Science & technology
   * Bioethics
   * Cell therapy
   * Research technologies
   * Research & technology centres
   * R&D pipeline
 * Partnering
   * Contact us about partnering
   * Our approach to partnering
   * Partnering interests
   * Partnering initiatives
 * Sustainable business
   * Our sustainability approach
   * Access & affordability
   * Zero environmental impact
   * Preventing chronic diseases
   * Defeat diabetes
   * Diversity & Inclusion
   * Preventing childhood overweight & obesity
   * ESG Portal
 * Careers
   * Find a job
   * Job agent
   * Working at Novo Nordisk
   * Early Career
   * Career areas
   * Event calendar - meet us
 * About us
   * Our heritage
   * What we do
   * Who we are
   * Corporate governance
   * Executive Management
   * Board of Directors
   * Our scientific approach
   * Our sustainability approach
 * Our products
   * Pens and needles
   * Our medicines
   * Smart Pens, Devices and Apps
   * Instructions for use
 * Investors
   * Investor highlights
   * Financial results, events and calendar
   * Annual Report 2023
   * Annual General Meeting 2024
   * ESG
   * Share information | Stock split
   * Investor Portal
   * Bond information
   * Company announcements and press releases
   * Contact Investor Relations
 * News & media
   * Latest news
   * Press releases
   * Partnership news
   * Media library
   * Contact Media Relations
   * Subscribe to press releases
   * Broadcast room
 * Patient help
   * Resources & support
   * Report a side effect
   * Report a product issue
   * Report falsified products
 * Healthcare professionals
 * Contact us
   * Contact overview
   * Find local information
   * Corporate procurement
   * Grants, donations, sponsorships & non-commercial partnerships
   * Report suspected misconduct
   * Report a security vulnerability

Novo Nordisk Global

DISCLAIMER STATEMENT


I do not agree
I agree

WARNING!


Ok Cancel



Novo Nordisk


PRESS RELEASE

11:58

24 May 2023

Announcement.pdf


NOVO NORDISK AND LIFE EDIT THERAPEUTICS ESTABLISH MULTI-TARGET COLLABORATION TO
DISCOVER AND DEVELOP GENE EDITING THERAPIES FOR RARE AND CARDIOMETABOLIC
DISEASES



Life Edit will receive an upfront cash payment and is eligible to receive
milestone payments of 250-335 million US dollars for each of seven development
programmes, as well as tiered royalties on global net sales.

Life Edit has the option to a global profit share on one programme.

Novo Nordisk will make an equity investment in ElevateBio, Life Edit’s parent
company, as part of ElevateBio’s 401 million US dollars Series D financing.

Bagsværd, Denmark and Durham, NC, US, 24 May 2023 – Novo Nordisk and Life Edit
Therapeutics, Inc., an ElevateBio company focused on next-generation gene
editing technologies and therapeutics, today announced a research and
development collaboration to discover and develop gene editing therapies against
a select set of therapeutic targets.

With a focus on advancing base editing capabilities, Novo Nordisk will leverage
Life Edit’s suite of gene editing technologies to precisely edit the genome with
the aim of developing life-changing therapies for rare genetic disorders as well
as more prevalent cardiometabolic diseases.

“At Novo Nordisk, we are committed to continuously building and leveraging
technology platforms that open up new opportunities across our therapeutic areas
to deliver potentially curative treatment options to people living with serious
chronic diseases,” said Marcus Schindler, PhD, professor, executive vice
president and chief scientific officer of Novo Nordisk. “We are excited about
the opportunity to co-create novel treatments for multiple genetic diseases
based on Life Edit’s gene editing technologies.”

Base editing is a method of gene editing that converts one nucleotide base (a
structural component of DNA) into another without cutting both strands of DNA.
This is achieved by coupling an enzyme known as a nuclease, modified to cut only
one DNA strand, to another enzyme known as a deaminase that edits the target
nucleotide base. This precision is intended to reduce the risk of off-target
effects and makes base editing a potentially effective approach for correcting
genetic mutations associated with diseases.

The collaboration between the two companies allows for development of up to
seven programmes. Under the agreement, Life Edit will receive an upfront cash
payment and is eligible to receive potential development, regulatory, and
commercial milestones of 335 million US dollars for each of the first two
development programmes under the collaboration and up to 250 million dollars for
each of the following five development programmes under the collaboration. Novo
Nordisk will be responsible for all research and development costs and Life Edit
is also eligible to receive tiered royalties on future net sales of therapeutic
products. In addition, Life Edit has an option to a global profit share on one
programme.

Moreover, Novo Nordisk will make an equity investment in ElevateBio, Life Edit’s
parent company, as part of ElevateBio’s 401 million US dollars Series D
financing.

“The advancements we’ve made to our next-generation gene editing platform and
base editing capabilities are opening the next frontier of treating disease
through DNA editing,” said Mitchell Finer, Ph.D., chief executive officer, Life
Edit Therapeutics and President, R&D, ElevateBio. “Combining our Life Edit
platform and the ability to make any edit anywhere with Novo Nordisk’s deep
disease biology and engineering expertise will bring us closer to delivering
potentially curative therapies for some of the world’s most challenging genetic
diseases.”

Life Edit is part of ElevateBio’s integrated ecosystem of R&D platform
technologies and end-to-end process development and cGMP manufacturing
capabilities built to power the creation of life-transforming cell and gene
therapies.

About Life Edit’s gene editing platform
Life Edit’s gene editing platform holds one of the world's largest and most
diverse libraries of novel RNA-guided nucleases (RGNs) and base editors that
provide flexible editing and unprecedented access to the genome. Life Edit’s
nuclease collection features a range of protospacer adjacent motifs (PAMs),
short sequences that determine the DNA segments in the genome to which a
nuclease can bind. The PAM diversity of Life Edit’s nucleases enables base
editing at more sites than any one nuclease could access, enabling the targeting
of genetic mutations in tighter windows and providing broad genome access.

About Life Edit Therapeutics Inc.
Life Edit Therapeutics, Inc., an ElevateBio company, is a next-generation genome
editing company that has built a highly innovative platform with one of the
world’s largest and most diverse collections of novel RNA-guided nucleases
(RGNs) and base editors. The platform allows Life Edit to target any genomic
sequence and potentially develop novel human therapeutics for the most
challenging genetic diseases by enabling ex vivo engineering for cell therapies
and regenerative medicines and in vivo delivery of gene therapies. In addition
to developing its own pipeline of cell and gene therapies, Life Edit will
continue to strengthen its platform of genome-editing enzymes, provide
gene-editing expertise to strategic partners, and form other third-party
partnerships to discover and develop new therapies.

For more information visit lifeeditinc.com or follow us on LinkedIn or Twitter

About ElevateBio
ElevateBio is a technology-driven company built to power the development of
transformative cell and gene therapies today and for many decades to come. The
company’s integrated technologies model offers turnkey scale and
biotechnological capabilities to power cell and gene therapy processes, programs
and companies to their full potential. The ElevateBio ecosystem combines
multiple R&D technology platforms – including Life Edit, a next-generation,
full-spectrum gene-editing platform; a proprietary induced pluripotent stem cell
(iPSC) platform, and an RNA, cell, protein, and vector engineering platform –
with BaseCamp®, its end-to-end genetic medicine cGMP manufacturing and process
development business, to power the discovery and development of advanced
therapeutics.

In addition to enabling a broad breadth of biopharmaceutical companies in the
development of their novel cell and gene therapies, ElevateBio is also building
a highly innovative pipeline of cellular, genetic, and regenerative medicines.
ElevateBio aims to be the dominant engine inside the world’s greatest scientific
advancements harnessing human cells and genes to alter disease. For more, visit
www.elevate.bio or follow ElevateBio on LinkedIn or Twitter.

About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and
headquartered in Denmark. Our purpose is to drive change to defeat diabetes and
other serious chronic diseases such as obesity and rare blood and endocrine
disorders. We do so by pioneering scientific breakthroughs, expanding access to
our medicines, and working to prevent and ultimately cure disease. Novo Nordisk
employs about 57,100 people in 80 countries and markets its products in around
170 countries. For more information, visit novonordisk.com, Facebook, Twitter,
LinkedIn and YouTube.

Novo Nordisk contacts for further information

Media: 

MARTIN HAVTORN PETERSEN

+45 3075 5246
mhpz@novonordisk.com



ALLISON SCHNEIDER (US)

+1 732 513 4875
aocd@novonordisk.com

Investors: 

DANIEL MUUSMANN BOHSEN

+45 3075 2175
dabo@novonordisk.com



JACOB MARTIN WIBORG RODE

+45 3075 5956
jrde@novonordisk.com



DAVID HEIBERG LANDSTED

+45 3077 6915
dhel@novonordisk.com



MARK JOSEPH ROOT (US)

+1 848 213 3219
mjhr@novonordisk.com



Life Edit/ElevateBio contacts

Company:Catherine Hu
chu@elevate.bioMedia:DJ Webster
dwebster@elevate.bio



 

 

Attachment

 * PR230524-Life-Edit





DOWNLOAD

Announcement.pdf

NOVO NORDISK HQ

Novo Nordisk A/S
Novo Alle 1
2880 Bagsværd
Denmark
+45-4444-8888
CVR-no. 24256790

 

Our medicines are for the approved indication for which they are authorised in
the local country or region. For more information, please visit our product page

Helpful links

Patient help Supplier help Product list Contact us Annual Report ESG reporting
Novo Nordisk Foundation

Follow us

LinkedIn YouTube Facebook X (Twitter) Instagram TikTok

Find your local office

Select location
© 2024 Novo Nordisk A/S

Data Privacy

Cookie policy

Cookie settings


change


WE VALUE YOUR PRIVACY

We use our own cookies as well as cookies from third parties. Cookies and the
related processing of your personal data are used to remember your settings,
traffic metrics, to present you with targeted adverts, and to track your use of
our website. You can withdraw or change your consent by clicking on the cookie
settings link at the bottom of this website. Your consent covers the use of
cookies and the related processing of your personal data. Here you may read more
on our Privacy policy Here you may read more on our cookie policy

Show details

Accept all cookiesOnly necessary cookies

STRICTLY NECESSARY

Always Active

These cookies are necessary for the website to function and cannot be switched
off in our systems. They are usually only set in response to actions made by you
which amount to a request for services, such as setting your privacy
preferences, logging in or filling in forms. You can set your browser to block
or alert you about these cookies, but some parts of the site will not then work.
These cookies do not store any personally identifiable information.

 * FUNCTIONAL
   
   Always Active
   
   These cookies enable the website to provide enhanced functionality and
   personalisation. They may be set by us or by third party providers whose
   services we have added to our pages. If you do not allow these cookies then
   some or all of these services may not function properly.

ANALYTICS

Analytics

These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They help us to know which pages are the
most and least popular and see how visitors move around the site. All
information these cookies collect is aggregated and therefore anonymous. If you
do not allow these cookies we will not know when you have visited our site, and
will not be able to monitor its performance.

TARGETING

Targeting

These cookies may be set through our site by our advertising partners. They may
be used by those companies to build a profile of your interests and show you
relevant adverts on other sites. They do not store directly personal
information, but are based on uniquely identifying your browser and internet
device. If you do not allow these cookies, you will experience less targeted
advertising.

OTHERS

Others

Unknown Category.

Back Button Performance Cookies



Vendor Search Search Icon
Filter Icon

Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label

Accept selected cookies